Ikarian Capital’s Adicet Bio ACET Stock Holding History

Ikarian Capital’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,881	Closed	-$1.24M	–	139
2022 Q1	$1.24M	Sell	3,881 -8,619	-69%	-$1.98M	0.16%	90
2021 Q4	$3.5M	Buy	+12,500	New	+$2.15M	0.52%	45

Other funds holding ACET

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ikarian Capital's ACET Position: Q3 2022 in Review

Ikarian Capital sold out of Adicet Bio (ACET) in Q3 2022, closing a stake of 8,951 shares — an estimated $2.09M sold.

Ikarian Capital first reported a position in ACET in Q2 2020 and held it in 9 quarters. The position peaked at $10.1M in Q1 2022. 102 funds tracked by Wall St. Rank hold ACET as of Q3 2022.

Ikarian Capital reported no remaining Adicet Bio position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 8,951 Adicet Bio shares in Q3 2022, an estimated $2.09M.
Ikarian Capital first reported a position in Adicet Bio in Q2 2020 and held it in 9 quarters.
Ikarian Capital's Adicet Bio position peaked at $10.1M in Q1 2022.
102 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.